GlassScriptPhysician profile
Lazaros Nikolaidis
NPI 1538157417
$4,732.07
in general payments reported to CMS, 2019-2025
18 companies · $310 in 2025
The $310 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $409 · 2020: $22.09 · 2021: $307 · 2022: $1,115 · 2023: $809 · 2024: $1,759 · 2025: $310.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,603 · Travel and Lodging: $276.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,602.51 |
| Travel and Lodging | $276.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,157.29 | 2021-2025 | Cardiomems, Thoratec Heartmate 3 Lvas Implant Kit |
| Abiomed | $884.96 | 2022-2024 | Impella |
| Cvrx, INC. | $531.49 | 2024-2025 | Barostim Neo System |
| Pfizer INC. | $530.06 | 2019-2025 | |
| Alnylam Pharmaceuticals INC. | $459.23 | 2019-2025 | Amvuttra, Onpattro |
| Impulse Dynamics (USA) INC. | $247.40 | 2023-2025 | Optimizer, Optimizer |
| E.R. Squibb & Sons, L.L.C. | $197.74 | 2021-2025 | Camzyos |
| Edwards Lifesciences Corporation | $169.81 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $146.41 | 2023 | Verquvo |
| Astrazeneca Pharmaceuticals LP | $119.74 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $65.44 | 2019-2024 | Jardiance |
| Janssen Scientific Affairs, LLC | $63.10 | 2025 | Rybrevant |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $45.79 | 2023-2025 | Lifevest |
| Medtronic, INC. | $45.12 | 2024 | Cobalt Dr Mri Surescan |
| Novo Nordisk INC | $30.43 | 2024 | Ozempic, Rybelsus |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $22.09 | 2020 | |
| Scpharmaceuticals INC. | $15.97 | 2024 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lazaros Nikolaidis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.